Tweet
Perrigo Company PLC (NYSE:PRGO) â€“ Equities researchers at Cantor Fitzgerald lowered their FY2019 EPS estimates for Perrigo in a research note issued on Monday, August 13th. Cantor Fitzgerald analyst L. Chen now forecasts that the company will post earnings of $5.33 per share for the year, down from their prior estimate of $5.59. Cantor Fitzgerald currently has a "Buy" rating and a $107.00 target price on the stock. Get Perrigo alerts:
Perrigo (NYSE:PRGO) last announced its quarterly earnings data on Thursday, August 9th. The company reported $1.22 EPS for the quarter, topping the Zacks' consensus estimate of $1.21 by $0.01. Perrigo had a return on equity of 11.92% and a net margin of 4.77%. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.23 billion. During the same period in the previous year, the company posted $1.22 earnings per share. The business's revenue for the quarter was down 4.2% on a year-over-year basis. A number of other equities analysts also recently commented on PRGO. Canaccord Genuity set a $105.00 price objective on Perrigo and gave the stock a "buy" rating in a research report on Monday, April 23rd. ValuEngine cut Perrigo from a "hold" rating to a "sell" rating in a research note on Wednesday, May 9th. Oppenheimer set a $98.00 target price on Perrigo and gave the stock a "buy" rating in a research note on Friday, May 11th. Wells Fargo & Co decreased their target price on Perrigo from $90.00 to $84.00 and set a "market perform" rating for the company in a research note on Monday, May 14th. Finally, TheStreet cut Perrigo from a "c-" rating to a "d+" rating in a research note on Thursday, May 31st. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and six have issued a buy rating to the stock. The company has an average rating of "Hold" and a consensus target price of $89.94.
Shares of Perrigo stock opened at $70.40 on Wednesday. Perrigo has a one year low of $67.53 and a one year high of $95.93. The stock has a market cap of $9.56 billion, a PE ratio of 14.28, a P/E/G ratio of 1.74 and a beta of 0.84. The company has a debt-to-equity ratio of 0.52, a current ratio of 1.81 and a quick ratio of 1.23.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 18th. Stockholders of record on Friday, August 31st will be issued a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a dividend yield of 1.08%. The ex-dividend date of this dividend is Thursday, August 30th. Perrigo's payout ratio is currently 15.42%.
In related news, EVP Svend Andersen bought 7,200 shares of the company's stock in a transaction dated Tuesday, August 14th. The shares were acquired at an average price of $69.43 per share, with a total value of $499,896.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website . Insiders own 6.90% of the company's stock.
A number of hedge funds have recently made changes to their positions in PRGO. Piedmont Investment Advisors LLC acquired a new position in Perrigo during the second quarter worth $110,000. Dupont Capital Management Corp grew its holdings in Perrigo by 63.8% during the second quarter. Dupont Capital Management Corp now owns 1,705 shares of the company's stock worth $124,000 after acquiring an additional 664 shares during the period. Twin Tree Management LP grew its holdings in Perrigo by 271.0% during the first quarter. Twin Tree Management LP now owns 2,223 shares of the company's stock worth $185,000 after acquiring an additional 3,523 shares during the period. Allianz Asset Management GmbH acquired a new position in Perrigo during the first quarter worth $205,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Perrigo during the first quarter worth $208,000. 80.89% of the stock is currently owned by hedge funds and other institutional investors.
Perrigo Company Profile
Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments